LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Prognostic Tool Found for Deadly Brain Cancer

By LabMedica International staff writers
Posted on 10 Jul 2012
Print article
A diagnosis of brain cancer is often fatal, but a novel technique shows that at least one subtype is associated with a longer life expectancy.

The innovative method subtypes glioblastoma multiforme (GBM) tumor lines by the proteins they express and this discovery could help with better patient prognoses and lead to targeted drug treatments for GBM subtypes.

At the University of Wisconsin (Madison, WI, USA) a group of scientists isolated tumor lines from five human patients and grew them in the laboratory, and then looked for biomarkers specific to each line. They later transplanted the tissue into the brains of mice with compromised immune systems. The antigenic expression of the protein biomarker called 2',3'-Cyclic-nucleotide 3'-phosphodiesterase (CNP), was used to evaluate a clinically-annotated GBM tissue microarray with 115 specimens.

The group found that some patients with the CNP protein lived much longer, as long as 10 years after diagnosis. Through protein expression analysis of developmental neural lineage markers, they identified glioblastoma stem-like cell (GSC) classes resembling oligodendrocyte progenitor cells (OPC) and neural progenitor cells; neural progenitor cells (NPC), and astrocyte progenitor cells. Each of these GSC types exhibited distinct and particular hallmarks found in GBM, including varied cellular and nuclear morphologies, invasive potential, and survival.

John S. Kuo, MD, PhD, an assistant professor and senior author of the study, said, "We found that this protein was correlated with a less invasive type of cancer in mice, and when we looked at samples of human tumors, remarkably, we also found that the less invasive tumors expressed the CNP protein." He added, "The subtyping could lead to more accurate prognosis for patients with a GBM diagnosis. Currently, most subtyping of GBM tumors are based on messenger ribonucleic acid (mRNA), which can be difficult to do, however most hospitals can run assays for proteins, making the test simpler and easier." The study was published on May 15, 2012, in the journal Clinical Cancer Research.

Related Links:

University of Wisconsin



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more